Literature DB >> 1731859

Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants.

B G Nordestgaard1, A Tybjaerg-Hansen, B Lewis.   

Abstract

To compare the atherogenic potential of low density lipoprotein (LDL), intermediate density lipoprotein (IDL), and very low density lipoprotein (VLDL) under conditions where plasma levels of these lipoproteins are elevated, the influx of cholesterol in these lipoproteins into the aortic intima was measured in vivo in genetically hyperlipidemic rabbits from the St. Thomas's Hospital strain, an animal model that shares many of the features of the human disorder familial combined hyperlipidemia. Univariate linear regression showed that the arterial influx of LDL cholesterol (n = 25), IDL cholesterol (n = 14), and VLDL cholesterol (n = 10) was positively and linearly associated with plasma concentrations of LDL cholesterol in the range 0.2-6.4 mmol/l, of IDL cholesterol in the range 0.1-7.0 mmol/l, and of VLDL cholesterol in the range 0.7-8.5 mmol/l, respectively, and also with the extent of lesions in the arterial intima in the range 0-100% of the surface area. Multiple linear regression suggested that the arterial influx of LDL, IDL, and VLDL cholesterol was linearly dependent on plasma concentration, independent of lesion size. Furthermore, it appeared that the arterial influx of the three lipoproteins was linearly dependent on the extent of the lesions, independent of lipoprotein concentration. When influx was normalized for plasma concentration (intimal clearance) and for lesion size (compared within the same aorta), the intimal clearance of the larger IDL and VLDL particles was 15-35% less than that of the smaller LDL particles. These findings suggest that the quantitatively most important mechanism for transfer of plasma lipoproteins into the arterial intima involves nonspecific molecular sieving and that at elevated plasma levels, IDL and VLDL share with LDL the potential for causing atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731859     DOI: 10.1161/01.atv.12.1.6

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  19 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  IDL, VLDL, chylomicrons and atherosclerosis.

Authors:  B G Nordestgaard; A Tybjaerg-Hansen
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

3.  Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes.

Authors:  P H Weinstock; C L Bisgaier; K Aalto-Setälä; H Radner; R Ramakrishnan; S Levak-Frank; A D Essenburg; R Zechner; J L Breslow
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta.

Authors:  L B Nielsen; S Stender; M Jauhiainen; B G Nordestgaard
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 5.  The role of hypertriglyceridemia in atherosclerosis.

Authors:  Ngoc-Anh Le; Mary F Walter
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

6.  The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques.

Authors:  Alessandra Barazza; Courtney Blachford; Orli Even-Or; Victor A Joaquin; Karen C Briley-Saebo; Wei Chen; Xian-Cheng Jiang; Willem J M Mulder; David P Cormode; Zahi A Fayad; Edward A Fisher
Journal:  Bioconjug Chem       Date:  2013-05-10       Impact factor: 4.774

Review 7.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

8.  Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus.

Authors:  Gissette Reyes-Soffer; Steve Holleran; Wahida Karmally; Colleen I Ngai; Niem-Tzu Chen; Margarita Torres; Rajasekhar Ramakrishnan; William S Blaner; Lars Berglund; Henry N Ginsberg; Catherine Tuck
Journal:  J Lipid Res       Date:  2009-05-08       Impact factor: 5.922

9.  Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL.

Authors:  Zareen M Farukhi; Olga V Demler; Michael P Caulfield; Krishnaji Kulkarni; Jay Wohlgemuth; Michael Cobble; Heike Luttmann-Gibson; Chunying Li; John R Nelson; Nancy R Cook; Julie E Buring; Ronald M Krauss; JoAnn E Manson; Samia Mora
Journal:  J Clin Lipidol       Date:  2020-02-21       Impact factor: 4.766

Review 10.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.